What is pilomatrix carcinoma?
Pilomatrix carcinoma is a rare skin cancer that starts in the hair follicle. It develops from matrix cells, the rapidly dividing cells at the base of the follicle that normally produce the hair shaft. It is also called pilomatrical carcinoma or malignant pilomatricoma.
It is the cancerous counterpart of pilomatricoma, a common benign lump that usually affects children and young adults. Pilomatrix carcinoma, by contrast, mostly affects middle-aged and older adults, and men much more often than women. It may arise on its own or, less commonly, within a previous pilomatricoma (Riva et al., 2025).
The tumour usually appears as a firm, painless lump in or under the skin, most often on the back of the neck, scalp or face. It is frequently mistaken for a cyst or another harmless lump, so the diagnosis is often made only after removal.
Pilomatrix carcinoma tends to grow into surrounding tissue and come back after surgery if not completely removed. Spread to other parts of the body is uncommon but possible, most often to the lungs (Jones et al., 2018). Complete surgical removal with clear margins is the key treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Malignant adnexal (skin appendage) tumour of hair follicle matrix cells |
| Also called | Pilomatrical carcinoma; malignant pilomatricoma |
| How common | Very rare; a few hundred cases reported |
| Typical age | Mostly 40-80; median around 60 |
| Sex | Men affected about 2-3 times as often as women |
| Main sites | Back of the neck, scalp, face, upper back and arms |
| Main treatment | Wide excision or Mohs micrographic surgery |
| Recurrence | Common after standard excision |
| Outlook | Good when fully removed; poorer if it spreads |
2. Types and related conditions
Pilomatricoma versus pilomatrix carcinoma
| Feature | Pilomatricoma (benign) | Pilomatrix carcinoma (malignant) |
|---|---|---|
| Usual age | Children and young adults | Older adults |
| Growth | Slow, stable | Can grow faster; may ulcerate |
| Edges under the microscope | Well defined | Infiltrative and irregular |
| Cell division | Low | High, with abnormal forms |
| Necrosis | Uncommon | Common |
| Recurrence after removal | Rare | Frequent |
| Spread | Never | Possible |
Forms of pilomatrix carcinoma
| Form | Notes |
|---|---|
| De novo | Arises without a known previous lump; the most common situation |
| Arising in a pilomatricoma | Develops in a pre-existing benign lesion or its scar |
| Recurrent | Returns at the original site, often after incomplete excision |
| Sarcomatoid variant | Very rare; contains spindle cells |
3. Causes and risk factors
The cause is not fully understood. Most tumours carry changes in the CTNNB1 gene, which makes the protein beta-catenin. Beta-catenin is part of the Wnt signalling pathway, which controls hair follicle growth. When it is switched on permanently, matrix cells keep dividing.
| Factor | Notes |
|---|---|
| Older age | Most patients are over 40 |
| Male sex | Clearly more common in men |
| Fair skin | Most reported patients are white |
| Previous pilomatricoma | Rarely, carcinoma develops in or near an old lesion |
| Incomplete excision | Raises the risk of recurrence |
The gene changes occur only in the tumour and are not inherited. Sun exposure has not been clearly linked with this tumour.
4. How does it look
On the skin
| Feature | Description |
|---|---|
| Shape | A firm, rounded nodule in the deeper skin |
| Size | Often 1-4 cm, sometimes much larger |
| Colour | Skin-coloured, red, purple or bluish |
| Surface | Usually smooth; may ulcerate or bleed |
| Feel | Hard, sometimes stony because of calcium deposits |
| Mobility | May become fixed to deeper tissues |
| Pain | Usually painless |
On scans
Ultrasound may show a solid nodule with calcified areas. MRI or CT is used for large or recurrent tumours to assess depth and involvement of muscle, bone or nerves. CT of the chest or PET-CT looks for spread to lymph nodes and lungs in higher-risk cases.
Under the microscope
| Feature | Description |
|---|---|
| Basaloid cells | Sheets of small, dark matrix-type cells |
| Ghost (shadow) cells | Pale cells that have lost their nucleus, typical of matrix tumours |
| Calcification | Common |
| Mitoses | Numerous, including abnormal forms |
| Necrosis | Frequently present |
| Growth pattern | Asymmetric and infiltrative |
| Stains | Nuclear beta-catenin and LEF1 positive |
The pathologist looks at the whole lesion, because a small biopsy may contain only benign-looking areas.
Sites of pilomatrix carcinoma
| Site | Notes |
|---|---|
| Back of the neck | One of the most frequent sites |
| Scalp | Common; may be hidden by hair |
| Face, including cheeks and around the ear | Mohs surgery is often preferred to spare tissue |
| Upper back and shoulders | Frequent in adults |
| Arms and legs | Less common |
5. Symptoms
Common symptoms
- A firm lump in or under the skin, especially on the back of the neck, scalp or face
- A lump that has grown over months
- A lump that feels hard or gritty
- Redness or bluish discolouration of the overlying skin
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Ulceration or bleeding | Advanced local growth |
| Pain or tenderness | Inflammation or deeper invasion |
| Lump returning at a scar | Local recurrence |
| Enlarged lymph nodes | Regional spread |
| Cough or breathlessness | Rarely, spread to the lungs |
When to seek medical advice
See a doctor about any new, growing or hard skin lump in an adult, particularly if it ulcerates, bleeds or reappears after removal. Many skin lumps are harmless, but persistent firm ones should be examined.
6. Diagnosis
| Test | Purpose |
|---|---|
| Skin examination | Assesses the lump and nearby lymph nodes |
| Excision or incisional biopsy | Provides tissue for diagnosis |
| Histopathology | Confirms carcinoma and checks margins |
| Immunohistochemistry | Supports the diagnosis and excludes look-alikes |
| Ultrasound of lymph nodes | Checks for regional spread |
| CT or PET-CT | For large, recurrent or high-risk tumours |
Conditions that can look similar
| Condition | Notes |
|---|---|
| Epidermoid cyst | Common harmless cyst; often the first clinical guess |
| Pilomatricoma | Benign counterpart |
| Basal cell carcinoma | Common skin cancer with basaloid cells |
| Merkel cell carcinoma | Aggressive neuroendocrine skin cancer |
| Metastasis from another cancer | Excluded with stains and scans |
Staging
There is no dedicated staging system. Doctors describe the size and depth of the tumour, whether it has recurred, and whether there is spread to lymph nodes or distant organs.
7. Treatment
Treatment is usually led by a skin cancer team, including dermatologists, dermatological or plastic surgeons and oncologists.
Surgery
| Option | Notes |
|---|---|
| Wide local excision | Removes the tumour with a margin of healthy tissue; the most common approach |
| Mohs micrographic surgery | Removes the tumour in thin layers, checking every margin under the microscope; spares healthy tissue |
| Reconstruction | Skin grafts or flaps for larger defects |
| Lymph node surgery | If nodes are involved |
A review of 101 published cases found no recurrences among 17 patients treated with Mohs surgery, compared with a recurrence rate of about 35% after standard excision, although follow-up was short (Riva et al., 2025).
Mohs surgery step by step
| Step | What happens |
|---|---|
| Local anaesthetic | The area is numbed; you stay awake |
| First layer | The visible tumour and a thin rim of tissue are removed |
| Mapping | The tissue is marked and colour-coded so its position is known |
| Microscope check | Every edge is examined while you wait, usually for about an hour |
| Further layers | More tissue is removed only where tumour remains |
| Repair | Once the margins are clear, the wound is stitched, grafted or left to heal |
Mohs surgery is especially useful on the face, scalp and neck, where saving healthy skin matters for appearance and function. It is not available everywhere, and it may take most of a day.
Radiotherapy
| Situation | Role |
|---|---|
| Close or positive margins | May lower the risk of recurrence |
| Tumours that cannot be removed | For local control |
| Spread to lymph nodes | Sometimes after node surgery |
| Painful metastases | Symptom relief |
Treatment of spread
There is no standard drug treatment. Chemotherapy has been tried in a few people with limited success. Treatment of metastatic disease is individualised, and clinical trials or molecular profiling of the tumour may be considered.
Side effects
| Treatment | Possible side effects |
|---|---|
| Excision | Scarring, wound healing problems, numbness near the scar |
| Mohs surgery | Longer procedure; small scar in most cases |
| Flaps or grafts | Colour or contour differences |
| Radiotherapy | Skin redness, hair loss in the treated area, tiredness |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Excision or Mohs surgery | Usually done under local anaesthetic as a day case |
| Larger reconstruction | May need a general anaesthetic and a short hospital stay |
| Wound care | Dressings and stitches removed after 1-2 weeks |
| Radiotherapy, if needed | Daily weekday sessions for a few weeks |
8. Outlook (prognosis)
| Factor | Effect on outlook |
|---|---|
| Complete removal with clear margins | Good long-term control |
| Local recurrence | Common; linked with a higher risk of spread (Herrmann et al., 2014) |
| Large or deeply invasive tumours | Higher risk |
| Lymph node or lung spread | Poorer outlook |
| Treatment at an experienced centre | Helps ensure clear margins and appropriate follow-up |
Most people who have the tumour completely removed do well. Because recurrence and later spread are possible, long-term follow-up is advised (Park, Wan and Khachemoune, 2025).
Why recurrence matters
Pilomatrix carcinoma sends thin, finger-like strands into the surrounding skin and fat. These strands can extend beyond what the surgeon can see or feel, so a standard excision may leave tumour behind.
When the cancer comes back, it often does so within the first two years, and each recurrence can be larger and more difficult to remove. A review of reported cases found that people whose tumour had recurred locally were more likely to develop metastases (Herrmann et al., 2014).
This is why surgeons aim for complete removal at the first operation, and why a second operation is often recommended if the margins are involved.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Skin and scar examination every 3-6 months at first | Detects local recurrence early |
| Lymph node examination | Checks the neck, armpits or groin |
| Imaging | Ultrasound or chest CT for higher-risk tumours |
| Annual reviews later | For at least 5 years |
10. Living with pilomatrix carcinoma
- Check your scar regularly and report any new lump
- Keep follow-up appointments, even if you feel well
- Protect healing scars from the sun to help them fade
- Ask about scar treatments such as massage or silicone gel
- Tell your doctor about any new lump elsewhere, including in the neck or armpit
- Keep a copy of your pathology report, as it helps if you see a new specialist
- Seek support from skin cancer charities and patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as a pilomatricoma? | No; pilomatricoma is benign, while pilomatrix carcinoma is its malignant form |
| Is it caused by the sun? | No clear link with sun exposure has been shown |
| Is it inherited? | No |
| Why did my lump come back? | Small strands of tumour can remain at the margins after excision |
| Is Mohs surgery better? | Early reports suggest fewer recurrences, but large studies are lacking |
| Will I need chemotherapy? | Rarely; surgery is the main treatment |
| Can it spread? | Occasionally, most often to the lungs or lymph nodes |
| How big a scar will I have? | It depends on the size and site of the tumour; Mohs surgery often keeps scars smaller |
| Can it occur in children? | Very rarely; lumps in children are almost always benign pilomatricomas |
12. Questions to ask your care team
- Were the margins clear?
- Would Mohs surgery or further excision be suitable for me?
- Do I need radiotherapy?
- Should I have scans to check for spread?
- How often will my follow-up be, and for how long?
- What signs of recurrence should I look out for?
- Is there a specialist skin cancer centre with experience of this tumour?
Resources
- Herrmann, J.L. et al. (2014) ‘Pilomatrix carcinoma: 13 new cases and review of the literature with emphasis on predictors of metastasis’, Journal of the American Academy of Dermatology, 71(1), pp. 38-43.
- Jones, C. et al. (2018) ‘Pilomatrix carcinoma: 12-year experience and review of the literature’, Journal of Cutaneous Pathology, 45(1), pp. 33-38.
- Park, A., Wan, L. and Khachemoune, A. (2025) ‘Pilomatrix carcinoma unveiled: a systematic review of clinical characteristics, pathogenesis, diagnostic puzzles, and management strategies’, Archives of Dermatological Research, 317(1), 278.
- Riva, H.R. et al. (2025) ‘Surgical treatment of pilomatrix carcinoma: a systematic review’, International Journal of Dermatology, 64(6), pp. 1021-1026.
Prepared by the editorial team, October 2026.